Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
•
Medical Oncology
Can palliative whole abdominal chemoradiation benefit nonoperative patients with extensive peritoneal carcinomatosis?
How would different pathologies affect your decision? What regimen would you recommend?
Related Questions
For a patient with a lung tumor that is radiographically consistent with early-stage NSCLC but pathology with characteristics overlapping with upper GI origin, what additional diagnostic procedures would you consider before treating?
What are your top takeaways in GI Cancers from ASCO 2023?
Would you offer adjuvant chemotherapy or radiation to a resected MSS T3N0 high-rectal lesion with low anterior resection without pre-op therapy?
For a pedunculated rectal polyp found to be adenocarcinoma after endoscopic removal, with PNI as the only adverse feature, would you recommend additional treatment such as surgery or chemoradiation?
How do you counsel patients and partners of patients with HPV+ cancers regarding the HPV vaccine?
What are best practices for oncologists during the national platinum shortage?
How would you sequence treatment of a synchronous IC1 high-grade serous ovarian cancer and cT3N1 rectal cancer?
For a patient who has T4 squamous cell esophageal carcinoma on imaging, and who has biopsy-confirmed disease in an involved local lymph node, are EUS or EGD still indicated to complete workup?
How will the PROSPECT trial presented at ASCO 2023 change your current management of early rectal cancer?
For inoperable cholangiocarcinoma, do you recommend up-front chemotherapy prior to offering SBRT or combination chemoradiation?